Long-Term Data Boost MCO-010
Four-year RESTORE results will shed new light on the durability of Nanoscope’s mutation-agnostic optogenetic therapy
Clinical Scorecard: Long-Term Data Boost MCO-010
At a Glance
| Category | Detail |
|---|
| Condition | Retinitis Pigmentosa |
| Key Mechanisms | Optogenetic gene therapy using a genetically engineered synthetic opsin to restore light sensitivity in surviving retinal cells. |
| Target Population | Patients with retinal degeneration caused by photoreceptor loss. |
| Care Setting | In-office intravitreal injection. |
Key Highlights
- Ensure all highlights are directly supported by the source material.
Guideline-Based Recommendations
Diagnosis
Management
- Consider MCO-010 for patients with retinal degeneration due to photoreceptor loss, as indicated in the source.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with retinitis pigmentosa and severe vision loss.
MCO-010 is administered as a one-time intravitreal injection.
Clinical Best Practices
- Ensure all practices are directly sourced from the context.
Related Resources & Content
